Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
BackgroundIntravesical Bacillus Calmette–Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common.ObjectivesTo compare the efficacy and toxicity of intravesical BCG an...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2017-11-01
|
| シリーズ: | Frontiers in Oncology |
| 主題: | |
| オンライン･アクセス: | http://journal.frontiersin.org/article/10.3389/fonc.2017.00260/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|